Pharmaceutical development is governed not only by scientific discovery, but by the regulatory evidence required to establish quality, safety, efficacy and responsible clinical use. Written for B.Pharm Semester VII students under the PCI 2026 framework, this textbook develops Regulatory Affairs as an applied pharmaceutical discipline linking drug development, regulatory decision-making and protection of public health.The text progresses from regulatory principles, terminology and major authorities to drug discovery, non-clinical evaluation, regulatory documentation and clinical development.
It examines CDSCO and State Licensing Authorities in India, international agencies including the US FDA, EMA and PMDA, IND, NDA and ANDA pathways, Drug Master Files, bioequivalence, generic and phytopharmaceutical regulation, CTD, eCTD and ACTD submissions, overseas registration and post-approval changes. Clinical research phases, IRB and IEC functions, informed consent, Good Clinical Practice, trial monitoring and pharmacovigilance are integrated within the wider product lifecycle.
Clear explanations emphasise why regulatory requirements exist, how evidence is generated and documented, and how regulators use that evidence in review and approval. Jurisdiction-specific concepts are carefully distinguished, while historical provisions are placed in appropriate context.
外文書商品之書封，為出版社提供之樣本。實際出貨商品，以出版社所提供之現有版本為主。部份書籍，因出版社供應狀況特殊，匯率將依實際狀況做調整。
無庫存之商品，在您完成訂單程序之後，將以空運的方式為你下單調貨。為了縮短等待的時間，建議您將外文書與其他商品分開下單，以獲得最快的取貨速度，平均調貨時間為1~2個月。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。
